Independent research tool — not a government agency. Official notices govern.Refreshed
GrantsJunctionAmerican funding, sourcedMethodology
ForecastedResearch announcementOpportunity FOR-RFA-AG-26-019

Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials

National Institutes of Health · Department of Health and Human Services

At a glance

Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials is a forecasted federal grant opportunity from the National Institutes of Health (Department of Health and Human Services). The agency's forecast estimates an application due date of October 5, 2025; forecast dates can change. Applicant types listed as eligible include state governments, county governments, independent school districts, public colleges & universities, federally recognized tribal governments and 6 more. Cost sharing is not required. It is funded under Assistance Listing 93.866 (Aging Research).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

  1. Jun 27, 2025Forecast posted
  2. Aug 1, 2025 (est.)Full notice expected
  3. Oct 5, 2025 (est.)Application deadline
  4. Jul 1, 2026 (est.)Est. award date
Posted
Jun 27, 2025
Est. close date
Oct 5, 2025
Est. award date
Jul 1, 2026
Award floor
Not specified
Award ceiling
Not specified
Est. total funding
Not specified
Expected awards
Not specified
Cost sharing
Not required
Funding instrument
Grant
Opportunity category
Discretionary
Fiscal year
FY2026

Typical awards for this program (SAM.gov listing for ALN 93.866, not this notice): Awards vary in range depending on the particular activity codes. Individual fellowships range from $23,376 to $57,504 and average about $46,000. Research grants have much larger ranges - from $75,000 to several million dollars. Average costs of research grants are around $400,000. All costs are shown on a single year basis. Awards may be for up to five years.

Who can apply

  • State governments
  • County governments
  • Independent school districts
  • Public colleges & universities
  • Federally recognized tribal governments
  • Public & Indian housing authorities
  • Native American tribal organizations
  • 501(c)(3) nonprofits
  • Private colleges & universities
  • For-profit organizations (not small businesses)
  • Small businesses

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and AD-related dementias (ADRD) using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. Working with the ACTC is a collaborative venture between the applicant, NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. The work of this NOFO will enable the testing of interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the R01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this NOFO. 

How to apply

0 of 8 done · progress saved in this browser

Assistance Listing

What is an ALN?

Reported obligations under ALN 93.866

Historical data · not a prediction
FY24$3.75B
FY25$3.78B
FY26$262M est.
Source: SAM.gov Assistance Listing 93.866. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

Laurie Ryan, Ph.D. National Institute on Aging (NIA)
ryanl@mail.nih.gov
301-496-9350

Quick answers

Is “Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials” open for applications yet?

Not yet. It is a forecast — an agency's advance notice of an expected opportunity. The agency estimates posting the full notice around August 1, 2025. Forecast details and dates can change.

Who is eligible to apply for “Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials”?

The official notice lists these applicant types as eligible: State governments, County governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Private colleges & universities, For-profit organizations (not small businesses) and Small businesses. Additional restrictions may apply; review the full notice.

How do I apply for “Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity FOR-RFA-AG-26-019), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.